ELORAC, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.eloracpharma.com
Clinical Trials
3
Active:0
Completed:2
Trial Phases
3 Phases
Phase 1:1
Phase 2:1
Phase 3:1
Drug Approvals
9
FDA:9
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (33.3%)Phase 2
1 (33.3%)Phase 3
1 (33.3%)Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
Phase 3
Terminated
- Conditions
- Mycosis FungoidesSézary SyndromeLymphoma, T-Cell, Cutaneous
- Interventions
- Drug: Placebo Lotion
- First Posted Date
- 2016-06-23
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Elorac, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT02811783
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
Finasteride Treatment of Severe Nodulocystic Acne
Phase 2
Completed
- Conditions
- NODULOCYSTIC ACNE
- Interventions
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Elorac, Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT02502669
- Locations
- 🇺🇸
Omni Dermatology, Inc., Phoenix, Arizona, United States
🇺🇸Burke Pharmaceutical Research, Hot Springs, Arkansas, United States
🇺🇸Dr. Ronald Moy, Beverly Hills, California, United States
Evaluate the Effect of Elimune Capsules
Phase 1
Completed
- Conditions
- Plaque Psoriasis
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2015-12-08
- Lead Sponsor
- Elorac, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT02251678
- Locations
- 🇺🇸
NMFF Dermatology Clinic, Chicago, Illinois, United States
🇺🇸NM Lake Forest Hospital/ Women's Center, Lake Forest, Illinois, United States
🇺🇸TKL Research, Fair Lawn, New Jersey, United States
News
No news found